Skip to main content
. 2014 Nov 20;112(2):313–318. doi: 10.1038/bjc.2014.561

Figure 1.

Figure 1

(A) Sensitivity of CRC cell lines to cetuximab based on TL independent of KRas mutation status. Exponentially growing human-derived CRC cells were treated with cetuximab at 20 μM for 72 h, and cell viability determined. The cell lines with short TL were less sensitive than cell lines with long TL (P=0.02). (B) Sensitivity of CRC cell lines to cetuximab based on TL in KRas WT cell lines. Sensitivity to cetuximab was determined specifically in the KRas WT cell lines. The cell lines with short TL were less sensitive than those with long TL (P=0.04). (C) Sensitivity of CRC cell lines to chemotherapy/preventive agents based on TL. Cell lines were treated with 8 other drugs and GI50 determined. We failed to find any association of the response to these drugs with TL with all P-values of >0.05.